Acute lymphoblastic leukemia displays a distinct highly methylated genome.


Journal

Nature cancer
ISSN: 2662-1347
Titre abrégé: Nat Cancer
Pays: England
ID NLM: 101761119

Informations de publication

Date de publication:
06 2022
Historique:
received: 18 05 2021
accepted: 25 03 2022
pubmed: 20 5 2022
medline: 30 6 2022
entrez: 19 5 2022
Statut: ppublish

Résumé

DNA methylation is tightly regulated during development and is stably maintained in healthy cells. In contrast, cancer cells are commonly characterized by a global loss of DNA methylation co-occurring with CpG island hypermethylation. In acute lymphoblastic leukemia (ALL), the commonest childhood cancer, perturbations of CpG methylation have been reported to be associated with genetic disease subtype and outcome, but data from large cohorts at a genome-wide scale are lacking. Here, we performed whole-genome bisulfite sequencing across ALL subtypes, leukemia cell lines and healthy hematopoietic cells, and show that unlike most cancers, ALL samples exhibit CpG island hypermethylation but minimal global loss of methylation. This was most pronounced in T cell ALL and accompanied by an exceptionally broad range of hypermethylation of CpG islands between patients, which is influenced by TET2 and DNMT3B. These findings demonstrate that ALL is characterized by an unusually highly methylated genome and provide further insights into the non-canonical regulation of methylation in cancer.

Identifiants

pubmed: 35590059
doi: 10.1038/s43018-022-00370-5
pii: 10.1038/s43018-022-00370-5
pmc: PMC9236905
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

768-782

Subventions

Organisme : NCI NIH HHS
ID : P30 CA021765
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197695
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA196172
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

Jeong, M. et al. Large conserved domains of low DNA methylation maintained by Dnmt3a. Nat. Genet. 46, 17–23 (2014).
pubmed: 24270360 doi: 10.1038/ng.2836
Michalak, E. M., Burr, M. L., Bannister, A. J. & Dawson, M. A. The roles of DNA, RNA and histone methylation in ageing and cancer. Nat. Rev. Mol. Cell Biol. 20, 573–589 (2019).
pubmed: 31270442 doi: 10.1038/s41580-019-0143-1
Su, J. et al. Homeobox oncogene activation by pan-cancer DNA hypermethylation. Genome Biol. 19, 108 (2018).
pubmed: 30097071 pmcid: 6085761 doi: 10.1186/s13059-018-1492-3
Feinberg, A. P., Gehrke, C. W., Kuo, K. C. & Ehrlich, M. Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res. 48, 1159–1161 (1988).
pubmed: 3342396
Cheng, P. et al. Alterations in DNA methylation are early, but not initial, events in ovarian tumorigenesis. Br. J. Cancer 75, 396–402 (1997).
pubmed: 9020485 pmcid: 2063379 doi: 10.1038/bjc.1997.64
Piyathilake, C. J. et al. Immunohistochemical evaluation of global DNA methylation: comparison with in vitro radiolabeled methyl incorporation assay. Biotech. Histochem. 75, 251–258 (2000).
pubmed: 11131565 doi: 10.3109/10520290009085128
The Blueprint Consortium. Quantitative comparison of DNA methylation assays for biomarker development and clinical applications. Nat. Biotechnol. 34, 726–737 (2016).
Berman, B. P. et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat. Genet. 44, 40–46 (2011).
pubmed: 22120008 pmcid: 4309644 doi: 10.1038/ng.969
Zhou, W. et al. DNA methylation loss in late-replicating domains is linked to mitotic cell division. Nat. Genet. 50, 591–602 (2018).
pubmed: 29610480 pmcid: 5893360 doi: 10.1038/s41588-018-0073-4
Johnstone, S. E. et al. Large-scale topological changes restrain malignant progression in colorectal cancer. Cell 182, 1474–1489 (2020).
pubmed: 32841603 pmcid: 7575124 doi: 10.1016/j.cell.2020.07.030
Russler-Germain, D. A. et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 25, 442–454 (2014).
pubmed: 24656771 pmcid: 4018976 doi: 10.1016/j.ccr.2014.02.010
Turcan, S. et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479–483 (2012).
pubmed: 22343889 pmcid: 3351699 doi: 10.1038/nature10866
Ley, T. J. et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363, 2424–2433 (2010).
pubmed: 21067377 pmcid: 3201818 doi: 10.1056/NEJMoa1005143
Weissmann, S. et al. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia 26, 934–942 (2012).
pubmed: 22116554 doi: 10.1038/leu.2011.326
Greenblatt, S. M. & Nimer, S. D. Chromatin modifiers and the promise of epigenetic therapy in acute leukemia. Leukemia 28, 1396–1406 (2014).
pubmed: 24609046 pmcid: 5555411 doi: 10.1038/leu.2014.94
Mullighan, C. G. The molecular genetic makeup of acute lymphoblastic leukemia. Hematology Am. Soc. Hematol. Educ. Program 2012, 389–396 (2012).
pubmed: 23233609 doi: 10.1182/asheducation.V2012.1.389.3798360
Alexander, T. B. & Mullighan, C. G. Molecular biology of childhood leukemia. Annu. Rev. Cancer Biol. 5, 95–117 (2021).
doi: 10.1146/annurev-cancerbio-043020-110055
Tasian, S. K., Loh, M. L. & Hunger, S. P. Philadelphia chromosome-like acute lymphoblastic leukemia. Blood 130, 2064–2072 (2017).
pubmed: 28972016 pmcid: 5680607 doi: 10.1182/blood-2017-06-743252
Zhang, J. et al. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat. Genet. 48, 1481–1489 (2016).
pubmed: 27776115 pmcid: 5144107 doi: 10.1038/ng.3691
Holmfeldt, L. et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat. Genet. 45, 242–252 (2013).
pubmed: 23334668 pmcid: 3919793 doi: 10.1038/ng.2532
Milani, L. et al. DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood 115, 1214–1225 (2010).
pubmed: 19965625 doi: 10.1182/blood-2009-04-214668
Nordlund, J. & Syvanen, A. C. Epigenetics in pediatric acute lymphoblastic leukemia. Semin. Cancer Biol. 51, 129–138 (2018).
pubmed: 28887175 doi: 10.1016/j.semcancer.2017.09.001
Taylor, K. H. et al. Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res. 67, 2617–2625 (2007).
pubmed: 17363581 doi: 10.1158/0008-5472.CAN-06-3993
Milani, L. et al. Allele-specific gene expression patterns in primary leukemic cells reveal regulation of gene expression by CpG site methylation. Genome Res. 19, 1–11 (2009).
pubmed: 18997001 pmcid: 2612957 doi: 10.1101/gr.083931.108
Davidsson, J. et al. The DNA methylome of pediatric acute lymphoblastic leukemia. Hum. Mol. Genet. 18, 4054–4065 (2009).
pubmed: 19679565 doi: 10.1093/hmg/ddp354
Stumpel, D. J. et al. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood 114, 5490–5498 (2009).
pubmed: 19855078 doi: 10.1182/blood-2009-06-227660
Figueroa, M. E. et al. Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. J. Clin. Invest. 123, 3099–3111 (2013).
pubmed: 23921123 pmcid: 3696550 doi: 10.1172/JCI66203
Wahlberg, P. et al. DNA methylome analysis of acute lymphoblastic leukemia cells reveals stochastic de novo DNA methylation in CpG islands. Epigenomics 8, 1367–1387 (2016).
pubmed: 27552300 doi: 10.2217/epi-2016-0052
Lee, S. T. et al. Epigenetic remodeling in B-cell acute lymphoblastic leukemia occurs in two tracks and employs embryonic stem cell-like signatures. Nucleic Acids Res. 43, 2590–2602 (2015).
pubmed: 25690899 pmcid: 4357708 doi: 10.1093/nar/gkv103
Almamun, M. et al. Integrated methylome and transcriptome analysis reveals novel regulatory elements in pediatric acute lymphoblastic leukemia. Epigenetics 10, 882–890 (2015).
pubmed: 26308964 pmcid: 4622668 doi: 10.1080/15592294.2015.1078050
Haider, Z. et al. An integrated transcriptome analysis in T-cell acute lymphoblastic leukemia links DNA methylation subgroups to dysregulated TAL1 and ANTP homeobox gene expression. Cancer Med. 8, 311–324 (2019).
pubmed: 30575306 doi: 10.1002/cam4.1917
Roels, J. et al. Aging of preleukemic thymocytes drives CpG island hypermethylation in T-cell acute lymphoblastic leukemia. Blood Cancer Discov. 1, 274–289 (2020).
pubmed: 33179015 pmcid: 7116343 doi: 10.1158/2643-3230.BCD-20-0059
Poole, C. J., Lodh, A., Choi, J. H. & van Riggelen, J. MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL. Epigenetics Chromatin 12, 41 (2019).
pubmed: 31266538 pmcid: 6604319 doi: 10.1186/s13072-019-0278-5
Roberts, K. G. et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N. Engl. J. Med. 371, 1005–1015 (2014).
pubmed: 25207766 pmcid: 4191900 doi: 10.1056/NEJMoa1403088
Flavahan, W. A., Gaskell, E. & Bernstein, B. E. Epigenetic plasticity and the hallmarks of cancer. Science https://doi.org/10.1126/science.aal2380 (2017).
Hansen, K. D. et al. Increased methylation variation in epigenetic domains across cancer types. Nat. Genet. 43, 768–775 (2011).
pubmed: 21706001 pmcid: 3145050 doi: 10.1038/ng.865
Meissner, A. et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454, 766–770 (2008).
pubmed: 18600261 pmcid: 2896277 doi: 10.1038/nature07107
Brinkman, A. B. et al. Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation. Nat. Commun. 10, 1749 (2019).
pubmed: 30988298 pmcid: 6465362 doi: 10.1038/s41467-019-09828-0
Ball, M. P. et al. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat. Biotechnol. 27, 361–368 (2009).
pubmed: 19329998 pmcid: 3566772 doi: 10.1038/nbt.1533
Aran, D., Toperoff, G., Rosenberg, M. & Hellman, A. Replication timing-related and gene body-specific methylation of active human genes. Hum. Mol. Genet. 20, 670–680 (2011).
pubmed: 21112978 doi: 10.1093/hmg/ddq513
Yang, X. et al. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell 26, 577–590 (2014).
pubmed: 25263941 pmcid: 4224113 doi: 10.1016/j.ccr.2014.07.028
Maunakea, A. K. et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 466, 253–257 (2010).
pubmed: 20613842 pmcid: 3998662 doi: 10.1038/nature09165
Baylin, S. B. & Jones, P. A. Epigenetic determinants of cancer. Cold Spring Harb. Perspect. Biol. https://doi.org/10.1101/cshperspect.a019505 (2016).
De, S. et al. Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genet. 9, e1003137 (2013).
pubmed: 23326238 pmcid: 3542081 doi: 10.1371/journal.pgen.1003137
Pan, H. et al. Epigenomic evolution in diffuse large B-cell lymphomas. Nat. Commun. 6, 6921 (2015).
pubmed: 25891015 doi: 10.1038/ncomms7921
Liao, J. et al. Targeted disruption of DNMT1, DNMT3A and DNMT3B in human embryonic stem cells. Nat. Genet. 47, 469–478 (2015).
pubmed: 25822089 pmcid: 4414868 doi: 10.1038/ng.3258
Wang, Y. et al. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. Mol. Cell 57, 662–673 (2015).
pubmed: 25601757 pmcid: 4336627 doi: 10.1016/j.molcel.2014.12.023
Smiraglia, D. J. et al. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum. Mol. Genet. 10, 1413–1419 (2001).
pubmed: 11440994 doi: 10.1093/hmg/10.13.1413
Paz, M. F. et al. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res. 63, 1114–1121 (2003).
pubmed: 12615730
Ogino, S. et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 55, 1000–1006 (2006).
pubmed: 16407376 pmcid: 1856352 doi: 10.1136/gut.2005.082933
Roessler, J. et al. The CpG island methylator phenotype in breast cancer is associated with the lobular subtype. Epigenomics 7, 187–199 (2015).
pubmed: 25347269 doi: 10.2217/epi.14.74
Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510–522 (2010).
pubmed: 20399149 pmcid: 2872684 doi: 10.1016/j.ccr.2010.03.017
Toyota, M. et al. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96, 8681–8686 (1999).
pubmed: 10411935 pmcid: 17576 doi: 10.1073/pnas.96.15.8681
Borssen, M. et al. Promoter DNA methylation pattern identifies prognostic subgroups in childhood T-cell acute lymphoblastic leukemia. PLoS ONE 8, e65373 (2013).
pubmed: 23762353 pmcid: 3675104 doi: 10.1371/journal.pone.0065373
Schlesinger, Y. et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 39, 232–236 (2007).
pubmed: 17200670 doi: 10.1038/ng1950
Widschwendter, M. et al. Epigenetic stem cell signature in cancer. Nat. Genet. 39, 157–158 (2007).
pubmed: 17200673 doi: 10.1038/ng1941
Smith, Z. D. et al. Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer. Nature 549, 543–547 (2017).
pubmed: 28959968 pmcid: 5789792 doi: 10.1038/nature23891
Parry, A., Rulands, S. & Reik, W. Active turnover of DNA methylation during cell fate decisions. Nat. Rev. Genet. 22, 59–66 (2021).
pubmed: 33024290 doi: 10.1038/s41576-020-00287-8
Alexander, T. B. et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature 562, 373–379 (2018).
pubmed: 30209392 pmcid: 6195459 doi: 10.1038/s41586-018-0436-0
Gu, Z. et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat. Genet. 51, 296–307 (2019).
pubmed: 30643249 pmcid: 6525306 doi: 10.1038/s41588-018-0315-5
Verma, N. et al. TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells. Nat. Genet. 50, 83–95 (2018).
pubmed: 29203910 doi: 10.1038/s41588-017-0002-y
Xi, Y. & Li, W. BSMAP: whole genome bisulfite sequence MAPping program. BMC Bioinf. 10, 232 (2009).
doi: 10.1186/1471-2105-10-232
McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).
pubmed: 20644199 pmcid: 2928508 doi: 10.1101/gr.107524.110
Sun, D. et al. MOABS: model based analysis of bisulfite sequencing data. Genome Biol. 15, R38 (2014).
pubmed: 24565500 pmcid: 4054608 doi: 10.1186/gb-2014-15-2-r38
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
pubmed: 23104886 doi: 10.1093/bioinformatics/bts635
Pertea, M. et al. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat. Biotechnol. 33, 290–295 (2015).
pubmed: 25690850 pmcid: 4643835 doi: 10.1038/nbt.3122
Liu, Y. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat. Genet. 49, 1211–1218 (2017).
pubmed: 28671688 pmcid: 5535770 doi: 10.1038/ng.3909
Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841–842 (2010).
pubmed: 20110278 pmcid: 2832824 doi: 10.1093/bioinformatics/btq033
Kolde, R. Pheatmap: pretty heatmaps. R Package v.61, 1–7 (2012).
Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847–2849 (2016).
pubmed: 27207943 doi: 10.1093/bioinformatics/btw313
Hetzel, S., Giesselmann, P., Reinert, K., Meissner, A. & Kretzmer, H. RLM: Fast and simplified extraction of read-level methylation metrics from bisulfite sequencing data. Bioinformatics https://doi.org/10.1093/bioinformatics/btab663 (2021).
Ren, W. et al. Direct readout of heterochromatic H3K9me3 regulates DNMT1-mediated maintenance DNA methylation. Proc. Natl Acad. Sci. USA 117, 18439–18447 (2020).
pubmed: 32675241 pmcid: 7414182 doi: 10.1073/pnas.2009316117
Dixon, G. et al. QSER1 protects DNA methylation valleys from de novo methylation. Science https://doi.org/10.1126/science.abd0875 (2021).
Yu, W. et al. Genome-wide DNA methylation patterns in LSH mutant reveals de-repression of repeat elements and redundant epigenetic silencing pathways. Genome Res. 24, 1613–1623 (2014).
pubmed: 25170028 pmcid: 4199375 doi: 10.1101/gr.172015.114
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281 pmcid: 4302049 doi: 10.1186/s13059-014-0550-8
Liao, Y., Wang, J., Jaehnig, E. J., Shi, Z. & Zhang, B. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 47, W199–w205 (2019).
pubmed: 31114916 pmcid: 6602449 doi: 10.1093/nar/gkz401
Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50, 163–170 (1966).
pubmed: 5910392

Auteurs

Sara Hetzel (S)

Department of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany.

Alexandra L Mattei (AL)

Department of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany.
Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA.

Helene Kretzmer (H)

Department of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany.

Chunxu Qu (C)

Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.

Xiang Chen (X)

Department of Computational Biology, St Jude Children's Research Hospital, Memphis, TN, USA.

Yiping Fan (Y)

Center for Applied Bioinformatics, St Jude Children's Research Hospital, Memphis, TN, USA.

Gang Wu (G)

Center for Applied Bioinformatics, St Jude Children's Research Hospital, Memphis, TN, USA.

Kathryn G Roberts (KG)

Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.

Selina Luger (S)

Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.

Mark Litzow (M)

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

Jacob Rowe (J)

Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.

Elisabeth Paietta (E)

Department of Oncology, Montefiore Medical Center, Bronx, NY, USA.

Wendy Stock (W)

University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.

Elaine R Mardis (ER)

Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, USA.

Richard K Wilson (RK)

Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, USA.

James R Downing (JR)

Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.

Charles G Mullighan (CG)

Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA. Charles.Mullighan@stjude.org.

Alexander Meissner (A)

Department of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany. meissner@molgen.mpg.de.
Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA. meissner@molgen.mpg.de.
Broad Institute of MIT and Harvard, Cambridge, MA, USA. meissner@molgen.mpg.de.
Department of Biology, Chemistry and Pharmacy, Freie Universität, Berlin, Germany. meissner@molgen.mpg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH